Epitope-specific treatment of experimental autoimmune encephalomyelitis with a novel MHC class II/peptide construct

G. G. Burrows, B. F. Bebo, K. L. Adlard, B. Siklodi, A. A. Vandenbark, H. Offner

Research output: Contribution to journalArticle

Abstract

Novel single chain MHC class II constructs consisting of only the β1 and α1 domains were produced in E. coli covalently linked to an encephalitogenic peptide known to induce T cell mediated experimental autoimmune encephalomyelitis (EAE) in Lewis rats, or complexed with these peptides after purification. The β1α1/MBP-72-89 complex bound specifically to and inhibited activation of MBP-72-89 reactive T cells, and fully suppressed clinical and histological signs of EAE, blocking activation and recruitment of inflammatory T cells into the CNS. Moreover, this complex completely arrested progression of ongoing disease, inhibiting T cell activation in an IL-2 reversible manner. The potent biological properties of this new class of small soluble polypeptides provide a template for human homologues useful for detecting and deleting potentially pathogenic T cells specific for organ specific autoantigens.

Original languageEnglish (US)
Pages (from-to)A1086
JournalFASEB Journal
Volume12
Issue number5
StatePublished - Mar 20 1998

ASJC Scopus subject areas

  • Biotechnology
  • Biochemistry
  • Molecular Biology
  • Genetics

Fingerprint Dive into the research topics of 'Epitope-specific treatment of experimental autoimmune encephalomyelitis with a novel MHC class II/peptide construct'. Together they form a unique fingerprint.

  • Cite this